Clinical trials: Hormone Replacement
MPS 7, Sly Syndrome
A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)
The Phase 3 study will use a novel randomized, intra-subject placebo-controlled, single crossover design, referred to as Blind Start, to evaluate the safety and efficacy of UX003.
- Conditions
- MPS 7, Sly Syndrome, Mucopolysaccharidosis, MPS VII
- Trial name
- NCT02230566
- Testing
- UX003
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Pompe Disease, Hypersensitivity Reaction
A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated Reaction
Hypothesis: the effectiveness of treatment of Pompe disease with rhGAA enzyme replacement therapy (ERT) is limited at least in part because patients develop antibodies against the provided rhGAA enzyme.
- Trial name
- NCT02185651
- Testing
- Zavesca® Prescription
- Volunteers
- 2 people
- Sponsor
- University of Florida
Hypoactive Sexual Desire Disorder
Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido
This study is designed to evaluate efficacy and safety of a testosterone patch as treatment for low libido in surgically menopausal women who are taking estrogen therapy.
- Trial name
- NCT00331123
- Testing
- Testosterone Transdermal System
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 562 people
- Sponsor
- Warner Chilcott
Neonatal Abstinence Syndrome
The Alberta Neonatal Abstinence Syndrome Mother-Baby Care ImprovEmeNT Program
Neonatal Abstinence Syndrome (NAS), is a common and costly problem in Alberta that affects approximately 250 babies per year exposed to drugs during pregnancy. Unfortunately, this has become more common in the last 10 years.
- Trial name
- NASCENT (NCT05226624)
- Testing
- Rooming-in care, Baseline standard of care
- Where
- Canada
- Volunteers
- 240 people
- Sponsor
- University of Alberta
Chimeric Antigen Receptor T-cell Therapy, B Cell Acute Lymphoblastic Leukemia (B-ALL)
Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell Lymphoma
B cell (CD19) targeted chimeric antigen receptor modified T Cells (CAR-T) has transformed treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) or B-cell lymphoma (BCL).
- Conditions
- Chimeric Antigen Receptor T-cell Therapy, B Cell Acute Lymphoblastic Leukemia (B-ALL), B Cell Lymphoma, Antibiotic Prophylaxis
- Trial name
- PREV-CART (NCT07754682)
- Testing
- Immunoglobulin, antibiotic prophylaxis
- Volunteers
- 228 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Frozen Embryo Transfer
Benefit of Amlodipine in HRT Cycle for Frozen Embryo Transfer in the Correction of Uterine Pulsatility Index
Embryo implantation depends on two main factors: embryo grading quality and endometrial receptivity.Numerous tools have been suggested to evaluate these two factors.
- Trial name
- AMLODIP (NCT04954196)
- Testing
- Amlodipine 5mg
- Volunteers
- healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Bietti Crystalline Corneoretinal Dystrophy, Bietti Crystalline Dystrophy
Efficacy and Safety of ZVS101e in Patients With Bietti 's Crystalline Dystrophy
This is a multi-center, randomized and controlled phase 3 clinical trial.
- Trial name
- NCT06743646
- Testing
- ZVS101e
- Where
- 5 sites in China
- Volunteers
- 63 people
- Sponsor
- Chigenovo Co., Ltd
Hemophilia A, Hemophilia B
Data Registry in Chinese Hemophilia A and B Patients
This is an open-label, prospective, multi-center, patient registry in Chinese Hemophilia A and B patients treated with anti-hemophilic coagulation factor replacement therapy.
- Trial name
- NCT07101224
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
COVID-19, Acute Kidney Injury
A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy
The purpose of this study is to assess the safety and tolerability of the investigational product, SBI-101, in subjects with an infectious etiology of Acute Kidney Injury (AKI).
- Conditions
- COVID-19, Acute Kidney Injury, Sepsis
- Trial name
- NCT04445220
- Testing
- SBI-101
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Sentien Biotechnologies, Inc.
Smoking Cessation, HIV Infections
Quit For Life (QFL): Smoking Cessation Among Chinese Smokers Living With HIV
The purpose of this two arm randomized clinical trial (RCT) is to test if a smoking cessation program called Quit for Life (QFL) which was developed by the investigators is effective for patients in China with HIV who smoke.
- Trial name
- QFL (NCT05020899)
- Testing
- Sessions with a trained counselor, Cell phone messages, Offered nicotine replacement therapy
- Where
- 2 sites in United States, China
- Volunteers
- 109 people
- Sponsor
- Boston Medical Center
Acute Kidney Injury, Intensive Care
The Cost-effectiveness of Artificial Intelligence Acute Kidney Injury Prediction Auxiliary Software (Acura AKI)
"Huede" AI Aided AKI Prediction Software, Acura AKI, uses machine learning algorithms to predict the risk of AKI within the next 24 hours and provide a ranking of feature importance.
- Conditions
- Acute Kidney Injury, Intensive Care, Renal Replacement Therapy
- Trial name
- NCT06685367
- Testing
- Acura AKI
- Where
- Taiwan
- Volunteers
- 3,600 people
- Sponsor
- Huede Healthtech Co., Ltd.
Smoking
Phase I Study: Stop Smoking Therapy for Ontario Patients (STOP)
20% of Ontarians smoke. There was a decline in smoking prevalence from 1995 but it has remained unchanged since 2002. This rate of smoking cessation has not kept up with the rest of Canada.
- Trial name
- NCT00356993
- Testing
- Nicotine Replacement Therapy, behavioural intervention
- Where
- Canada
- Volunteers
- 6,009 people
- Sponsor
- Centre for Addiction and Mental Health
Acute Kidney Injury
Proenkephalin A and Kidney Replacement Therapy
Acute kidney injury (AKI) is a common problem encountered in the intensive care unit (ICU), estimated to occur in up to 60% of all critically ill patients, depending on the definition.
- Trial name
- NCT04879706
- Testing
- None planned
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- University of Giessen
Idiopathic Hypogonadotropic Hypogonadism
The Effects of Gonadotropin Replacement Therapy in Patients With Hypogonadism
Effects of hCG replacement therapy on metabolic syndrome parameters in hypogonadotrophic hypogonadism.
- Trial name
- NCT02042638
- Testing
- hCG 1500 IU three times a week, Pregnyl (hCG) ampule 1500 IU/three times a week
- Where
- Turkey (Türkiye)
- Volunteers
- 16 people
- Sponsor
- Gulhane School of Medicine
Spinal Muscular Atrophy
AveXis Managed Access Program Cohort for Access to AVXS-101
The purpose of this Cohort Treatment Protocol will allow access to AVXS-101 for eligible patients diagnosed with SMA.
- Trial name
- NCT03955679
- Testing
- AVXS-101
- Where
- United States
- Sponsor
- United BioSource, LLC
Acute Kidney Injury
Trial to Assess the Efficacy and Safety of Nafamostat Mesilate During Continuous Renal Replacement Therapy
Randomized study to evaluate the efficacy and safety of nafamostat mesilate use during continuous renal replacement therapy in acute kidney injury patients at a high risk of bleeding.
- Trial name
- NCT02478242
- Testing
- Nafamostat mesilate, Normal saline
- Volunteers
- 60 people
- Sponsor
- Kyungpook National University Hospital
Gaucher Disease, Type 1
Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease
Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB). Due to the deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular…
- Trial name
- NCT00954460
- Testing
- velaglucerase alfa
- Where
- 32 sites in United States
- Sponsor
- Shire
Hypoinsulinemia
Transdermally Delivered Human Insulin Product
An Early Feasibility Study of a device formulation to deliver human insulin across intact skin
- Trial name
- NCT03544996
- Testing
- TD Insulin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Transdermal Delivery Solutions Corp
Premature Ovarian Insufficiency
Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency
Background: Premature ovarian insufficiency (POI) is a condition in which women under the age of 40 years have absent or irregular menstrual cycles. POI can cause infertility, signs of menopause, osteoporosis, and other symptoms.
- Trial name
- NCT06851754
- Testing
- Progesterone, Estrogen Patch
- Where
- United States
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Hypomagnesemia
Dynamic Magnesium Replacement Strategies and 28-Day Mortality in Non-Cardiac Critically Ill Patients With Hypomagnesemia: A Target Trial Emulation
This study looks at how different ways of giving magnesium (a nutrient) affect the risk of death within 28 days for adults with low magnesium levels who are in the intensive care unit (ICU) for non-heart-related reasons.
- Trial name
- NCT07380542
- Where
- China
- Volunteers
- 12,887 people
- Sponsor
- Fujian Provincial Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.